Last reviewed · How we verify
Edema in nephrotic syndrome with inadequate response to other treatments — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aldactone | Spironolactone | Pfizer Inc. | Potassium-sparing diuretic, aldosterone antagonist | Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer Inc. · 1 drug in Edema in nephrotic syndrome with inadequate response to other treatments
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Edema in nephrotic syndrome with inadequate response to other treatments:
- Edema in nephrotic syndrome with inadequate response to other treatments treatment updates — RSS
- Edema in nephrotic syndrome with inadequate response to other treatments treatment updates — Atom
- Edema in nephrotic syndrome with inadequate response to other treatments treatment updates — JSON
Cite this brief
Drug Landscape (2026). Edema in nephrotic syndrome with inadequate response to other treatments — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/edema-in-nephrotic-syndrome-with-inadequate-response-to-other-treatments. Accessed 2026-06-10.
Related
- Edema in nephrotic syndrome with inadequate response to other treatments full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing